Surgical Science Sweden AB (publ) (STO:SUS)

Market Cap	1.80B -74.8%
Revenue (ttm)	977.14M +3.2%
Net Income	52.21M -63.0%
EPS	1.02 -62.9%
Shares Out	51.03M
PE Ratio	34.54
Forward PE	14.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,375
Open	37.20
Previous Close	37.40
Day's Range	35.24 - 37.20
52-Week Range	23.70 - 162.60
Beta	0.57
Analysts	Buy
Price Target	59.80 (+69.21%)
Earnings Date	May 20, 2026

About STO:SUS

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnosti...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1997
• Employees: 313
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SUS

Financial Performance

In 2025, STO:SUS's revenue was 992.34 million, an increase of 12.25% compared to the previous year's 884.09 million. Earnings were 66.82 million, a decrease of -49.24%.